Myriad Genetics Management

Management criteria checks 2/4

Myriad Genetics' CEO is Paul Diaz, appointed in Aug 2020, has a tenure of 4.25 years. total yearly compensation is $12.11M, comprised of 9% salary and 91% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth €5.95M. The average tenure of the management team and the board of directors is 2.4 years and 4.8 years respectively.

Key information

Paul Diaz

Chief executive officer

US$12.1m

Total compensation

CEO salary percentage	9.0%
CEO tenure	4.3yrs
CEO ownership	0.4%
Management average tenure	2.4yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Diaz's remuneration changed compared to Myriad Genetics's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$116m
Jun 30 2024	n/a	n/a	-US$155m
Mar 31 2024	n/a	n/a	-US$235m
Dec 31 2023	US$12m	US$1m	-US$263m
Sep 30 2023	n/a	n/a	-US$274m
Jun 30 2023	n/a	n/a	-US$248m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$11m	US$1m	-US$112m
Sep 30 2022	n/a	n/a	-US$77m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$13m	US$1m	-US$27m
Sep 30 2021	n/a	n/a	-US$57m
Jun 30 2021	n/a	n/a	-US$97m
Mar 31 2021	n/a	n/a	-US$148m
Dec 31 2020	US$16m	US$383k	-US$224m

Compensation vs Market: Paul's total compensation ($USD12.11M) is above average for companies of similar size in the German market ($USD1.64M).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.

CEO

Paul Diaz (62 yo)

4.3yrs

Tenure

US$12,108,359

Compensation

Mr. Paul J. Diaz serves as the Member of Advisory Board at Thornton Capital, LLC. He has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He serves a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Diaz	CEO, President & Director	4.3yrs	US$12.11m	0.44% € 5.9m
Samraat Raha	Chief Operating Officer	less than a year	US$5.02m	no data
Dale Muzzey	Chief Scientific Officer	2.8yrs	US$2.23m	0.12% € 1.6m
Mark Verratti	Chief Commercial Officer	7.3yrs	US$2.88m	0.32% € 4.3m
Scott Leffler	Chief Financial Officer	less than a year	no data	no data
Natalie Munk	Principal Accounting Officer	2.4yrs	no data	0.048% € 643.5k
Kevin Haas	Chief Technology Officer	3.8yrs	US$1.64m	0.14% € 1.9m
Matthew Scalo	Senior Vice President of Investor Relations	no data	no data	no data
Jennifer Fox	Chief Legal Officer	less than a year	no data	no data
Glenn Farrell	Senior VP & Chief Marketing Officer	1.9yrs	no data	no data
Shereen Solaiman	Chief People Officer	1.7yrs	no data	0.0031% € 42.5k
Patrick Burke	Executive Vice President of Strategy & Innovation	3.5yrs	no data	no data

2.4yrs

Average Tenure

51yo

Average Age

Experienced Management: MYD's management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Diaz	CEO, President & Director	4.3yrs	US$12.11m	0.44% € 5.9m
Paul Bisaro	Independent Director	2.1yrs	US$258.48k	0.027% € 363.7k
Lee Newcomer	Independent Director	5.2yrs	US$447.99k	0.073% € 991.4k
Daniel Skovronsky	Independent Director	4.3yrs	US$433.49k	0.077% € 1.0m
Colleen Reitan	Independent Director	5.2yrs	US$443.49k	0.029% € 399.2k
Heinrich Dreismann	Independent Director	14.4yrs	US$443.49k	0.12% € 1.6m
S. Phanstiel	Independent Chair of the Board	15.2yrs	US$563.49k	0.16% € 2.2m
Rashmi Kumar	Independent Director	4.2yrs	US$433.49k	0.068% € 917.7k

4.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: MYD's board of directors are considered experienced (4.8 years average tenure).

Myriad Genetics Management

Management criteria checks 2/4

Key information

Recent management updates

Independent Director recently sold €245k worth of stock

Insider recently sold €288k worth of stock

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

CEO, President & Director recently sold €5.3m worth of stock

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Recent updates

Third quarter 2024 earnings released: US$0.24 loss per share (vs US$0.75 loss in 3Q 2023)

Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

New minor risk - Share price stability

Myriad Genetics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Now 22% undervalued after recent price drop

Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024

Myriad Genetics, Inc. to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference

Independent Director recently sold €245k worth of stock

Insider recently sold €288k worth of stock

Second quarter 2024 earnings released: US$0.41 loss per share (vs US$1.42 loss in 2Q 2023)

Myriad Genetics, Inc. Raises Earnings Guidance for the Full Year 2024

Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer, Effective September 3, 2024

Myriad Genetics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

New minor risk - Financial position

CEO, President & Director recently sold €5.3m worth of stock

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.67 loss in 1Q 2023)

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings released: US$3.18 loss per share (vs US$1.39 loss in FY 2022)

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Myriad Genetics, Inc. has completed a Follow-on Equity Offering in the amount of $109.999996 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings released: US$0.75 loss per share (vs US$0.43 loss in 3Q 2022)

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$1.42 loss per share (vs US$0.17 loss in 2Q 2022)

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.26 loss in 1Q 2022)

Full year 2022 earnings released: US$1.39 loss per share (vs US$0.35 loss in FY 2021)

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.31 profit in 3Q 2021)

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.061 loss in 2Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2022

Myriad Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Myriad Genetics, Inc. Announces the Resignation of Dennis Langer as Director

Myriad Genetics, Inc. Announces Executive Changes

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

First quarter 2022 earnings released: US$0.26 loss per share (vs US$0.52 loss in 1Q 2021)

Myriad Genetics, Inc. Provides Earnings Guidance for the Fiscal Year 2022

High number of new directors

Myriad Genetics, Inc., Annual General Meeting, Jun 02, 2022

Myriad Genetics, Inc. Settles the Qui Tam Lawsuit with STF, LLC

Forecast to breakeven in 2024

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Investor sentiment deteriorated over the past week